Videos

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval and what it means for Wegovy 7.2 mg in the US.

This new February episode of the Skin of Color Savvy podcast highlights why 2026 may be the year of skin health equity in the dermatology field.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal Pump's recent Breakthrough Designation from the FDA.

KONFIDENT investigator Cancian discusses oral sebetralstat’s role in the updated HAE treatment guidelines.

Survey of 600 US relatives finds donor–recipient closeness and expected life extension drive living kidney donation more than financial concerns.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent release of the Eversense 365 by Sequel Medtech and Senseonics, paired with the Twiist insulin pump.

Levine discusses 24-hour adverse event resolution, retreatment questions, and scalability of supervised psilocybin therapy for treatment-resistant depression.

This interview segment highlights additional points on bimekizumab and psoriasis related to patient-reported outcomes (PROs) in the 3 year BE RADIANT study.

In this segment of his interview, Vender highlighted his own views on the significance of BE RADIANT trial findings on bimekizumab for psoriasis.

SEQUENCE trial data highlight sustained 3-year clinical and endoscopic remission with risankizumab in anti-TNF–exposed Crohn’s patients.

This interview with Vender highlights recent findings on patient-reported outcomes (PROs) in patients in the BE RADIANT trial with psoriasis.

Panaccione recaps interim PROFUNDUS data showing real-world efficacy and safety of upadacitinib (Rinvoq) for ulcerative colitis.

Hurtado-Lorenzo explains the growing interest in meal timing as a potential lifestyle intervention for Crohn’s and recent trial data supporting its utility in this patient population.

Ezekowitz discusses his recent secondary analysis of the SODIUM-HF trial, highlighting the MAGGIC analysis data that implied a very limited benefit.

Targeting CD28 and CD154 pathways, dual blockade with belatacept and dazodalibep offers potential to improve adherence in kidney transplant recipients.

Barnes reviews 3-year VIVID-2 data showing durable remission, steroid-free control, and stable safety with mirikizumab in moderate-to-severe Crohn’s disease.

This segment of the latest Skin of Color Savvy episode highlights discoid lupus in skin of color, housing barriers, and Medicaid navigation.

Targeting CD28 and CD154 pathways, dual blockade with belatacept and dazodalibep offers a new mechanistic approach in kidney transplant care.

Anouti outlines why early bilirubin testing and emerging serum markers are key to improving prognosis in biliary atresia.

Marsan and Santi discuss their recent study highlighting the need for lower LVESVi thresholds in aortic valve surgery in women to reduce mortality outcomes.

New data show limited uptake of SBS-specific ICD-10 codes, raising concerns about misclassification and the true burden of disease.

Navar discusses the positive data from the phase 3 trial and emphasizes substantial treatment adherence throughout the 52-week period.

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

Stocker discusses the potential for a wearable patch to continuous drug measurement of vancomycin, especially in pediatric patients and outpatient settings.

This clip from the latest episode of the Skin of Color Savvy podcast highlights Kazemi's experiences as a dermatologist working to help underserved communities.

Diabetes Dialogue Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the patient awareness motivation behind Novo Nordisk’s recent announcement.

Rizik and Morris discuss the Heartflow PCI Navigator and its promising implications for patients – and how they manage that excitement while waiting for trial data.

This Skin of Color Savvy episode featured Abrahem Kazemi, MD, who speaks on several notable experiences he had as a dermatologist.